Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomas, J.
Right arrow Articles by Klein, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, J.
Right arrow Articles by Klein, E. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 15 (August), 2002: 3213-3218
© 2002 American Society for Clinical Oncology

Preoperative Combined Nested Reverse Transcriptase Polymerase Chain Reaction for Prostate-Specific Antigen and Prostate-Specific Membrane Antigen Does Not Correlate With Pathologic Stage or Biochemical Failure in Patients With Localized Prostate Cancer Undergoing Radical Prostatectomy

By John Thomas, Manjula Gupta, Ying Grasso, Chandana A. Reddy, Warren D. Heston, Craig Zippe, Robert Dreicer, Patrick A. Kupelian, Jennifer Brainard, Howard S. Levin, Eric A. Klein

From the Urological Institute, Taussig Cancer Center, Lerner Research Institute, and Departments of Clinical Pathology, Radiation Oncology, and Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH.

Address reprint requests to Eric A. Klein, MD, Urological Institute, Desk A100, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195; email: kleine{at}ccf.org

PURPOSE: We report a prospective study examining the ability of preoperative nested reverse transcriptase polymerase chain reaction (RT-PCR) for prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSM) to predict pathologic stage and biochemical recurrence in patients with clinically localized prostate cancer treated with radical prostatectomy.

PATIENTS AND METHODS: One hundred forty-one patients were entered onto the study. Preoperative evaluation included clinical T stage, serum PSA, biopsy Gleason score, and serum RT-PCR for PSA/PSM. Univariate and multivariate logistic regression models, Kaplan-Meier estimates, and Cox proportional hazards modeling were used to identify predictors of pathologic stage and biochemical failure.

RESULTS: Seventy-three patients (51.8%) were RT-PCR positive for PSA, PSM, or both. In the multivariate logistic regression model, only initial PSA was an independent predictor of pathologic stage as defined by organ-confined disease (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.00 to 1.13; P = .026) or organ-/specimen-confined disease (OR, 1.09; 95% CI, 1.02 to 1.16; P = .009). Overall Kaplan-Meier biochemical relapse-free survival (bRFS) was 85% at 59 months. Multivariate analysis of predictors for bRFS with the Cox proportional hazards model indicated that only initial PSA (OR, 1.05; 95% CI, 1.02 to 1.09; P = .004) and biopsy Gleason score (OR, 3.57; 95% CI, 1.37 to 9.58; P = .009) were independent predictors of biochemical failure. RT-PCR status did not predict pathologic stage or biochemical failure. Repeat analysis excluding 27 patients who received preoperative androgen-deprivation therapy did not change the results.

CONCLUSION: Combined nested RT-PCR for PSA and PSM is not an independent predictor of pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. This assay has no clinical utility in this patient population.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Clin. Chem.Home page
P. Helo, A. M. Cronin, D. C. Danila, S. Wenske, R. Gonzalez-Espinoza, A. Anand, M. Koscuiszka, R.-M. Vaananen, K. Pettersson, F. K.-H. Chun, et al.
Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival
Clin. Chem., April 1, 2009; 55(4): 765 - 773.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. M. Morgan, P. H. Lange, M. P. Porter, D. W. Lin, W. J. Ellis, I. S. Gallaher, and R. L. Vessella
Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence
Clin. Cancer Res., January 15, 2009; 15(2): 677 - 683.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Schmidt, G. DeAngelis, E. Eltze, I. Gockel, A. Semjonow, and B. Brandt
Asynchronous Growth of Prostate Cancer Is Reflected by Circulating Tumor Cells Delivered from Distinct, Even Small Foci, Harboring Loss of Heterozygosity of the PTEN Gene.
Cancer Res., September 15, 2006; 66(18): 8959 - 8965.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. C. Ferrari, N. N. Stone, R. Kurek, E. Mulligan, R. McGregor, R. Stock, P. Unger, U. Tunn, A. Kaisary, M. Droller, et al.
Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment
J. Clin. Oncol., July 1, 2006; 24(19): 3081 - 3088.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. W. Ross, J. Manola, K. Hennessy, M. Galsky, H. Scher, E. Small, W. K. Kelly, and P. W. Kantoff
Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-Specific Antigen in Men with Hormone-Refractory Prostate Cancer Treated with Chemotherapy
Clin. Cancer Res., July 15, 2005; 11(14): 5195 - 5198.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Patel, P. J. Whelan, S. Prescott, S. C. Brownhill, C. F. Johnston, P. J. Selby, and S. A. Burchill
The Use of Real-Time Reverse Transcription-PCR for Prostate-Specific Antigen mRNA to Discriminate between Blood Samples from Healthy Volunteers and from Patients with Metastatic Prostate Cancer
Clin. Cancer Res., November 15, 2004; 10(22): 7511 - 7519.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Kurek, G. Nunez, N. Tselis, L. Konrad, T. Martin, S. Roeddiger, G. Aumuller, N. Zamboglou, D. W. Lin, U. W. Tunn, et al.
Prognostic Value of Combined "Triple"-Reverse Transcription-PCR Analysis for Prostate-Specific Antigen, Human Kallikrein 2, and Prostate-Specific Membrane Antigen mRNA in Peripheral Blood and Lymph Nodes of Prostate Cancer Patients
Clin. Cancer Res., September 1, 2004; 10(17): 5808 - 5814.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
I. H.N. Wong
The Sporadic Nature of Shedding Cells in Blood: Multiple RNA Diagnostic Testing and Prognostication of Cancer Progression
Clin. Chem., September 1, 2003; 49(9): 1429 - 1431.
[Full Text] [PDF]


Home page
Cancer Res.Home page
S. F. Shariat, E. Gottenger, C. Nguyen, W. Song, M. W. Kattan, J. Andenoro, T. M. Wheeler, D. M. Spencer, and K. M. Slawin
Preoperative Blood Reverse Transcriptase-PCR Assays for Prostate-specific Antigen and Human Glandular Kallikrein for Prediction of Prostate Cancer Progression after Radical Prostatectomy
Cancer Res., October 15, 2002; 62(20): 5974 - 5979.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online